Abstract:Introduction: The major challenge to effective oncolytic viral-mediated cancer therapy is the lack of tumor-specific targeting. Myeloid derived suppressor cells (MDSCs) are immature myeloid cells induced by tumor factors which have been shown to migrate to tumors. Better understanding of the kinetics of MDSC migration may enable the use of MDSCs as delivery vectors for tumor-specific therapies. Vesicular Stomatitis Virus (VSV) is an oncolytic rhabdovirus which requires high doses for effective peripherally administered cancer therapy. These doses carry a likelihood of neurotoxic effects in humans. We hypothesize that MDSCs can improve delivery and decrease side effects of VSV therapy. Methods: Ly6C+ monocytic MDSCs were isolated from tumor-bearing BALB/c mice. Cells were stained with Feridex and PKH26 dye and adoptively transferred into BALB/c mice with intrahepatic MCA26 colon cancer. Mice received daily MRI and were sacrificed for FACS, relaxometry, or mass spectrometry. Intrahepatic MCA26 tumor-breaing mice were treated with injection of 5x106 MDSCs cultured with VSV or VSV(M3) virus (MOI:300), with or without α-VSV-G ab and compared for survival to mice receiving PBS, MDSCs alone, free virus, and Ly6c- cells cultured with VSV. Mice were sacrificed and organs harvested for histology and TCID50. Results: We demonstrate via MRI that MDSCs migrate to tumors in an adoptive transfer model of murine hepatic metastases of colon cancer. MDSC levels peak intratumorally 72 hrs after transfer and are identified peripherally and perivasciularly. Intratumoral MDSC levels are elevated compared to spleen (38±2%Injected Dose (%ID) vs 13±0.6%ID, 72hrs, p<0.001), and liver (0.5±1%ID, p<0.001) via mass spectrometry and relaxometry. This is confirmed by FACS, which shows a 7-fold increase of MDSC signaling in the tumor compared to background (p=0.001). We then employ MDSCs as a delivery vehicle for VSV. VSV-infected MDSCs significantly prolong survival in mice with hepatic colon cancer over systemic administration of VSV alone (29.8 days vs 24 days; p<0.0002). Furthermore, the improvement of VSV binding efficiency on MDSCs leads to significantly improved survival when VSV is conjugated to MDSCs using α-VSV-G ab (52.9 days vs 24.9 days; p<0.0001) demonstrating 26% overall survival and no significant toxicity. We confirm increased viral delivery to tumors and decreased delivery to other tissues through histology and TCID50, indicating an improved therapeutic index for VSV therapy when administered via MDSCs. Conclusions: This study demonstrates a proof-of-principle for MDSCs preferentially targeting therapeutics to metastatic tumors. in the future we anticipate that this technique may be applied to a variety of targeted tumor therapies.

Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System

[Advances in Measles Virus for Cancer Therapy].

Mitophagy Enhances Oncolytic Measles Virus Replication by Mitigating Ddx58/Rig-I-Like Receptor Signaling

Measles to the Rescue: A Review of Oncolytic Measles Virus

Engineered Measles Virus Edmonston Strain Used As a Novel Oncolytic Viral System Against Human Neuroblastoma Through a CD46 and Nectin 4-Independent Pathway

Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis

Oncolytic Measles Virus Enhances Antitumour Responses of Adoptive CD8+NKG2D+ Cells in Hepatocellular Carcinoma Treatment

Mitophagy Switches Cell Death from Apoptosis to Necrosis in NSCLC Cells Treated with Oncolytic Measles Virus.

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

Graphene Oxide Arms Oncolytic Measles Virus for Improved Effectiveness of Cancer Therapy.

Measles Virus as an Oncolytic Immunotherapy

Measles Virus for Cancer Therapy

Enhancing Therapeutic Efficacy of Oncolytic Vaccinia Virus Armed with Beclin-1, an Autophagic Gene in Leukemia and Myeloma.

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors

Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading

A Novel Role for Myeloid Derived Suppressor Cells in Tumor-specific Therapeutic Targeting

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Dichloroacetate Blocks Aerobic Glycolytic Adaptation to Attenuated Measles Virus and Promotes Viral Replication Leading to Enhanced Oncolysis in Glioblastoma

Chemokine Expression from Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus